Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Justin Ritz

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2020
Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral TherapyCatherine Godfrey, Michael D Hughes, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 31, 2020
Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy InitiationTrevor A Crowell, Justin Ritz, Robert W Coombs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2024
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19Nikolaus Jilg, Mark J Giganti, Kara W Chew, et al.
RNA (New York, N.Y.)|May 26, 2011
Sharing and archiving nucleic acid structure mapping dataPhilippe Rocca-Serra, Stanislav Bellaousov, Amanda Birmingham, et al.
The Journal of Infectious Diseases|August 31, 2023
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2019
Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited SettingsCarole L Wallis, Michael D Hughes, Justin Ritz, et al.
The Journal of Infectious Diseases|August 31, 2023
Immune Status and SARS-CoV-2 Viral DynamicsYijia Li, Carlee Moser, Evgenia Aga, et al.
The Journal of Infectious Diseases|April 22, 2017
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019Yijia Li, Linda J Harrison, Kara W Chew, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Eclinicalmedicine|September 10, 2024
Post-acute COVID-19 outcomes including participant-reported long COVID: amubarvimab/romlusevimab versus placebo in the ACTIV-2 trialTeresa H Evering, Carlee Moser, Nikolaus Jilg, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|February 13, 2020
Brief Report: Sex Differences in Outcomes for Individuals Presenting for Third-Line Antiretroviral TherapyCatherine Godfrey, Michael D Hughes, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 31, 2020
Novel Criteria for Diagnosing Acute and Early Human Immunodeficiency Virus Infection in a Multinational Study of Early Antiretroviral Therapy InitiationTrevor A Crowell, Justin Ritz, Robert W Coombs, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|July 17, 2024
SARS-CoV-2 Plasma Antibody and Nucleocapsid Antigen Status Predict Outcomes in Outpatients With COVID-19Nikolaus Jilg, Mark J Giganti, Kara W Chew, et al.
RNA (New York, N.Y.)|May 26, 2011
Sharing and archiving nucleic acid structure mapping dataPhilippe Rocca-Serra, Stanislav Bellaousov, Amanda Birmingham, et al.
The Journal of Infectious Diseases|August 31, 2023
Statistical Challenges When Analyzing SARS-CoV-2 RNA Measurements Below the Assay Limit of Quantification in COVID-19 Clinical TrialsCarlee B Moser, Kara W Chew, Mark J Giganti, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 15, 2019
Diverse Human Immunodeficiency Virus-1 Drug Resistance Profiles at Screening for ACTG A5288: A Study of People Experiencing Virologic Failure on Second-line Antiretroviral Therapy in Resource-limited SettingsCarole L Wallis, Michael D Hughes, Justin Ritz, et al.
The Journal of Infectious Diseases|August 31, 2023
Immune Status and SARS-CoV-2 Viral DynamicsYijia Li, Carlee Moser, Evgenia Aga, et al.
The Journal of Infectious Diseases|April 22, 2017
Clinical Trial of the Anti-PD-L1 Antibody BMS-936559 in HIV-1 Infected Participants on Suppressive Antiretroviral TherapyCynthia L Gay, Ronald J Bosch, Justin Ritz, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|October 9, 2022
Nasal and Plasma Severe Acute Respiratory Syndrome Coronavirus 2 RNA Levels Are Associated With Timing of Symptom Resolution in the ACTIV-2 Trial of Nonhospitalized Adults With Coronavirus Disease 2019Yijia Li, Linda J Harrison, Kara W Chew, et al.
Pageof 6